Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of alvimopan for opioid-induced bowel dysfunction in adults with persistent non-cancer pain
2005-001725-28Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced bowel dysfunction (OIBD) comparing Alvimopan 0.5 mg twice daily with Placebo (2 arms). Primary endpoint: Incidence of clinical adverse events. Started Jul 2005; status: completed.
02
Drugs
alvimopan
03
Conditions
opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on 2005-001725-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001725-28.